The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia by Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids

Get full text

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome by Ian M. Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Steven Kornblau, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal-Shamanna, Chitra Hosing, Sherry Pierce, Meghan Meyer, Xuelin Huang, Guillermo Garcia-Manero

Get full text

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase... by Mahesh Swaminathan, Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Navel G. Daver, Guillermo Garcia-Manero, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Guillermo Montalban-Bravo, Tapan M. Kadia, Yesid Alvarado, Elias J. Jabbour, Nicholas J. Short, William G. Wierda, Nitin Jain, Steven M. Kornblau, Lucia Masarova, Sherry A. Pierce, Wei Qiao, Jing Ning, Hagop Kantarjian, Marina Y. Konopleva

Get full text